Ceramide nanoliposomal - Keystone Nano

Drug Profile

Ceramide nanoliposomal - Keystone Nano

Alternative Names: Ceramide NanoLiposome; CNL; KN 001; KN-001 - Keystone Nano; KN-01; Nanoliposomal ceramide

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Keystone Nano
  • Class Antineoplastics; Ceramides; Neuroprotectants; Sphingolipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 15 Mar 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT02834611)
  • 05 Jan 2017 US FDA approves IND application for Ceramide nanoliposome in Cancer
  • 04 Jan 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top